SCHEDULE 13G/A: BlackRock Maintains Significant Passive Stake in Vericel Corp, Discloses 15.1% Ownership

BlackRock, Inc. has filed an Amendment No. 7 to its Schedule 13G, reaffirming its passive beneficial ownership of 15.1% of Vericel Corp's common stock.

Summary

• BlackRock, Inc. reported beneficial ownership of 7,570,280 shares of Vericel Corp common stock as of March 31, 2025.
• This ownership represents 15.1% of Vericel Corp's outstanding common stock.
• BlackRock holds sole voting power over 7,512,627 shares and sole dispositive power over 7,570,280 shares.
• The filing is an Amendment No. 7 to a Schedule 13G, indicating ongoing reporting of a passive investment.
• BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Vericel Corp.
• One of BlackRock's subsidiaries, iShares Core S&P Small-Cap ETF, is noted to have an interest exceeding five percent of the total outstanding common stock of Vericel Corp.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing (Schedule 13G/A) reporting beneficial ownership. It contains no subjective language, financial performance data, or strategic updates that would indicate a positive or negative sentiment. It is purely informational and neutral.

Positives

• Confirmation of a significant, long-term institutional investor (BlackRock) holding a substantial stake (15.1%) in Vericel Corp, which can signal confidence in the company's fundamentals.
• The passive nature of BlackRock's investment, as certified in the filing, suggests no immediate intent to influence or change the control of the issuer, providing stability.

Risks

• The document does not explicitly state risks for Vericel Corp, but BlackRock's certification confirms that their holding is not for the purpose of changing or influencing control, mitigating potential activist investor risks from this specific holding.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Vericel Corp's future performance or BlackRock's investment strategy beyond its passive intent.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing is a routine disclosure by a major institutional asset manager, BlackRock, regarding its passive investment in Vericel Corp. Such filings are common for large investment firms that hold significant, non-controlling stakes across numerous public companies as part of their diversified portfolio management strategies, often through index funds or ETFs. It reflects standard institutional investment activity within the broader market.

Comparison to Industry Standards

• BlackRock's 15.1% stake in Vericel Corp is a substantial passive holding, typical for large asset managers like BlackRock, Vanguard, or State Street, which often hold significant percentages of public companies through their various funds (e.g., iShares Core S&P Small-Cap ETF mentioned in the filing).
• The filing adheres to the standard regulatory requirements for beneficial ownership disclosure under Schedule 13G, which is used by passive investors holding over 5% of a company's stock, contrasting with Schedule 13D filings used by activist investors seeking to influence management or control.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional investor's continued passive stake, which may be viewed positively as a sign of long-term confidence in the company.
• Management: The certification of passive intent by BlackRock indicates that management is unlikely to face immediate pressure or activist demands from this specific shareholder.

Next Steps

• BlackRock, Inc. will continue to file amendments to its Schedule 13G as required by SEC regulations if there are material changes to its beneficial ownership of Vericel Corp common stock.

Key Dates

Keywords

Vericel Corp, BlackRock, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Passive Investment, SEC Filing